The recent advances in the field of tissue engineering has forever altered the course of human scientific history. With the advent of the necessary laboratory techniques to develop human tissues in vitro, researchers have gained the ability to manipulate nature in a remarkable manner. Tissue engineered skin, the first engineered organ to emerge from the lab to the marketplace, has opened the door to the a variety of other tissue engineered products. Living skin equivalents have proven successful in treating patients with FDA-approved indications and patients involved in controlled clinical trials examining future applications. One such living skin equivalent is Organogenesis and Novartis' Apligraf, which consists of a type-I collagen matrix seeded with fibroblasts and covered with a layer of cultured keratinocytes. On May 26, 1998, Apligraf was approved by the FDA to treat patients exhibiting venous leg ulcers. In the United States alone, approximately 1,000,000 people annually seek treatment for these lesions. In July of 2000, Apligraf was also approved for diabetic foot ulcer treatment, potentially improving the lives of another 800,000 Americans.